Methods and kits for identifying subjects responsive to arginine deprivation therapy
AssigneePolaris Pharmaceuticals, Inc.
InventorsHung-Wen Chen, Hui-Fen Liu, Chau-Ting Yeh, Yu-De Chu, Chun-Hung Chou
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and kits for identifying responsiveness or non-responsiveness of a cancer subject to arginine deprivation therapy. The method includes determining the presence of a G/G genotype of rs13338697 of the target nucleic acid in a biological sample derived from the subject by use of a polymerase chain reaction (PCR)-based method, in which the presence of the G/G genotype of rs13338697 of the target nucleic acid is an indication that the subject is responsive to the arginine deprivation therapy.
Claims5
A method for treating a subject suffering from a tumor comprising,
- obtaining a nucleic acid-containing sample from the subject;
- detecting the presence of a G/G genotype of rs13338697 in a target nucleic acid of the nucleic acid-containing sample by use of a polymerase chain reaction (PCR)-based method, wherein the PCR-based method comprises,
- amplifying the target nucleic acid in the nucleic acid-containing sample by a first forward primer of SEQ ID No:
- 1 or 2 and a first reverse primer of SEQ ID No:
- 3;
- and
- subjecting the subject to an arginine deprivation therapy when the G/G genotype of rs13338697 is present in the target nucleic acid.
Dependencies are inferred from the claim text.